Advertisement
Singapore markets open in 7 hours 23 minutes

  • Straits Times Index

    3,272.72
    +47.55 (+1.47%)
     

  • S&P 500

    5,069.63
    +59.03 (+1.18%)
     

  • Dow

    38,525.46
    +285.48 (+0.75%)
     

  • Nasdaq

    15,687.10
    +235.79 (+1.53%)
     

  • Bitcoin USD

    66,694.75
    +0.87 (+0.00%)
     

  • CMC Crypto 200

    1,434.24
    +19.48 (+1.38%)
     

  • FTSE 100

    8,044.81
    +20.94 (+0.26%)
     

  • Gold

    2,341.30
    -5.10 (-0.22%)
     

  • Crude Oil

    83.14
    +1.24 (+1.51%)
     

  • 10-Yr Bond

    4.5840
    -0.0390 (-0.84%)
     

  • Nikkei

    37,552.16
    +113.55 (+0.30%)
     

  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     

  • FTSE Bursa Malaysia

    1,561.64
    +2.05 (+0.13%)
     

  • Jakarta Composite Index

    7,110.81
    +36.99 (+0.52%)
     

  • PSE Index

    6,506.80
    +62.72 (+0.97%)
     

Zosano Pharma to Present at the H.C. Wainwright Global Life Sciences Conference

Zosano Pharma Corporation
·1-min read

FREMONT, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Global Life Sciences Conference which will be available on Tuesday, March 9, 2021 at 7:00 am ET.

A webcast of the event will be available on the company’s website at http://ir.zosanopharma.com/events-presentations. The archived webcast will remain available for 30 days following the date of the presentation.

About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company’s transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano’s lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine. Learn more at www.zosanopharma.com.

Zosano Contacts:
Christine Matthews
Chief Financial Officer
510-745-1200

Zosano PR:
Sylvia Wheeler or Alexandra Santos
swheeler@wheelhouselsa.com or asantos@wheelhouselsa.com